In last trading session, Adverum Biotechnologies Inc (NASDAQ:ADVM) saw 2.16 million shares changing hands with its beta currently measuring 0.86. Company’s recent per share price level of $1.52 trading at -$0.13 or -7.88% at ring of the bell on the day assigns it a market valuation of $315.48M. That closing price of ADVM’s stock is at a discount of -95.39% from its 52-week high price of $2.97 and is indicating a premium of 55.26% from its 52-week low price of $0.68. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.24 million shares which gives us an average trading volume of 2.16 million if we extend that period to 3-months.
Adverum Biotechnologies Inc (NASDAQ:ADVM) trade information
Upright in the red during last session for losing -7.88%, in the last five days ADVM remained trading in the red while hitting it’s week-highest on Friday, 03/15/24 when the stock touched $1.52 price level, adding 17.84% to its value on the day. Adverum Biotechnologies Inc’s shares saw a change of 101.91% in year-to-date performance and have moved -15.56% in past 5-day. Adverum Biotechnologies Inc (NASDAQ:ADVM) showed a performance of -22.45% in past 30-days. Number of shares sold short was 5.43 million shares which calculate 1.39 days to cover the short interests.
Adverum Biotechnologies Inc (ADVM) estimates and forecasts
Statistics highlight that Adverum Biotechnologies Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -4.40% of value to its shares in past 6 months, showing an annual growth rate of 33.62% while that of industry is 12.50. Apart from that, the company came raising its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to increase by 48.30% in the current quarter and calculating 54.80% increase in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 0.36% during past 5 years.
ADVM Dividends
Adverum Biotechnologies Inc is more likely to be releasing its next quarterly report between March 28 and April 01 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Adverum Biotechnologies Inc (NASDAQ:ADVM)’s Major holders
Insiders are in possession of 0.98% of company’s total shares while institution are holding 67.58 percent of that, with stock having share float percentage of 68.24%. Investors also watch the number of corporate investors in a company very closely, which is 67.58% institutions for Adverum Biotechnologies Inc that are currently holding shares of the company. Commodore Capital Lp is the top institutional holder at ADVM for having 10.0 million shares of worth $15.9 million. And as of Jun 29, 2023, it was holding 9.90% of the company’s outstanding shares.
The second largest institutional holder is FMR, LLC, which was holding about 7.76 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 7.68% of outstanding shares, having a total worth of $12.34 million.
On the other hand, Fidelity Select Portfolios – Biotechnology and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Aug 30, 2023, the former fund manager was holding 6.9 million shares of worth $12.01 million or 6.83% of the total outstanding shares. The later fund manager was in possession of 2.66 million shares on Jun 29, 2023, making its stake of worth around $4.23 million in the company or a holder of 2.64% of company’s stock.
